Journal Report

Future Oncology

Download PDF
Journal Information
Journal Title
Future Oncology
Publisher
Taylor and Francis Ltd.
ISSN
1479-6694
E-ISSN
1744-8301
Database
SCOPUS
Domain
Health Sciences, Life Sciences
Classification History
Year A+ A B C
2026 ✓ ✓
2025 ✓ ✓
2024 ✓ ✓
2023 ✓ ✓
2021/2022 ✓ ✓
2020 ✓ ✓
2019 ✓ ✓
2018 ✓
A journal may have more than one classification in the same year. All recorded classifications are displayed.
Recent Articles
Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS
Debu Tripathy, Joanne L. Blum, Meghan S. Karuturi et al.
2026-11-6 Pages 1-14
DOI: 10.1080/14796694.2026.2747581
Efficacy and safety of Disitamab Vedotin (RC48-ADC) monotherapy versus combination therapy with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis
Qing Liangliang, Li Lingyi, Li Xianyong et al.
2026-11-6 Pages 1-12
DOI: 10.1080/14796694.2026.2757484
Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05
Veronique Dieras, Giuseppe Curigliano, Miguel Martin et al.
2026-11-6 Pages 1-10
DOI: 10.1080/14796694.2026.2753928
Zanidatamab in the treatment of esophagogastric adenocarcinoma
Orla M. Fitzpatrick, Geoffrey Y. Ku
2026-11-6 Pages 1-11
DOI: 10.1080/14796694.2026.2760738
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
Dongsheng Yue, Federico Cappuzzo, Wenxiang Wang et al.
2026-11-6 Pages 1-11
DOI: 10.1080/14796694.2026.2743385
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC
Mehmet Altan, Vishal Navani, Hye Ryun Kim et al.
2026-11-6 Pages 1-12
DOI: 10.1080/14796694.2026.2752788
Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
Xiuning Le, Antonio Passaro, Yuanyuan Zhao et al.
2026-11-4 Pages 1-18
DOI: 10.1080/14796694.2026.2749355
Treatment patterns and characteristics of Chinese patients with advanced or resectable melanoma: a multicenter retrospective study
Yu Jiang, Junjie Gu, Yu Chen et al.
2026-11-1 Pages 1-12
DOI: 10.1080/14796694.2026.2744073
Study design of the phase III ADELA trial of elacestrant with or without everolimus in <i>ESR1</i> -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor
José Manuel Pérez-García, Antonio Llombart-Cussac, Elena López-Miranda et al.
2026-10-31 Pages 1-13
DOI: 10.1080/14796694.2026.2753794
Falcon – multicancer early detection (MCED) real-world evidence (RWE) registry
Ronan J. Kelly, Peter J. Hulick, Henry Mark Dunnenberger et al.
2026-10-30 Pages 1-9
DOI: 10.1080/14796694.2026.2753325
Articles retrieved from Crossref.
Green Journals | https://www.green-journals.com | info@green-journals.com
Printed: November 8, 2026 22:17